Persistent Suppression of Type 1 Diabetes by a Multicomponent Vaccine Containing a Cholera Toxin B Subunit-Autoantigen Fusion Protein and Complete Freund’s Adjuvant
Table 2
Analysis of hyperglycemia development.
Treatment
PBS (naive)
CFA (1 : 0)
CFA (1 : 10)
CFA (1 : 100)
rVV-CTB::GAD + CFA (1 : 0)
rVV-CTB::GAD + CFA (1 : 10)
rVV-CTB::GAD + CFA (1 : 100)
rVV-CTB::GAD
Groups
1
2
3
4
5
6
7
8
values/weeks*
Incidence of diabetes
1
PBS (naive)
<0.01/17–59 wks
≥0.05/19 wks and 31–37 wks
≥0.05/none
<0.01/ 17–105 wks
<0.001/ 17–61 wks
<0.01/ 17–51 wks
<0.01/ 17–43 wks
2
CFA (1 : 0)
<0.001
≥0.05/ none
<0.01/ 21–35 wks
≥0.05/ none
≥0.05/ 37–43 wks
≥0.05/ none
≥0.05/ none
3
CFA (1 : 10)
<0.05
<0.001
≥0.05/ 33 wks
<0.01/ 39–105 wks
<0.01/ 35–59 wks and 93–99 wks
≥0.05/ 39 wks
≥0.05/ 39 wks
4
CFA (1 : 100)
≥0.05
<0.001
≥0.05
<0.01/ 21–105 wks
<0.01/ 21–61 wks
<0.05/ 21–43 wks
<0.01/ 21–43 wks
5
rVV-CTB::GAD + CFA (1 : 0)
<0.001
<0.05
<0.001
<0.001
≥0.05/ none
≥0.05/ 103 wks
≥0.05/ 103 wks
6
rVV-CTB::GAD + CFA (1 : 10)
<0.001
<0.05
<0.001
<0.001
≥0.05
≥0.05/ 43 wks
≥0.05/ 43 wks
7
rVV-CTB::GAD + CFA (1 : 100)
<0.001
<0.05
<0.001
<0.001
<0.001
<0.001
≥0.05/ none
8
rVV-CTB::GAD
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
≥0.05
Blood glucose
value for each pair of groups was determined using two-tailed Mann-Whitney value. Test for equality of two proportions was used to determine those weeks when statistically significant differences ( values between −1.96 and +1.96) were detected.
